View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

FibroBiologics Files Patent Application Covering Fibroblast-based Tech...

FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent Office covering the use of FibroBiologics’ fibroblast cell-based technology for the potential t...

 PRESS RELEASE

Verizon Joins RE100 and Shares New Milestones in its Responsible Busin...

Verizon Joins RE100 and Shares New Milestones in its Responsible Business Plan NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Today, Verizon announced it has joined RE100, a global initiative bringing together the world’s most influential businesses committed to 100% renewable electricity. Led by the Climate Group and in partnership with CDP, RE100’s mission is to accelerate change towards zero carbon grids at scale, an objective that Verizon is proud to support. As previously announced, Verizon aims to source renewable energy equivalent to 100% of its annual electricity usage by 2030, with...

 PRESS RELEASE

Coinsilium Group Limited: Total Voting Rights

Coinsilium Group Limited (COIN) Coinsilium Group Limited: Total Voting Rights 28-March-2024 / 13:19 GMT/BST COINSILIUM GROUP LIMITED("Coinsilium" or the "Company")Total Voting Rights  London, UK, 28 March 2024 - In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, Coinsilium hereby announces that it has 217,464,234  ordinary shares of nil par value ("Ordinary Shares") in issue, each share carrying the right to one vote. The Company does not hold any Ordinary Shares in treasury. The figure of 217,464,234 Ordinary Shares may be used by shareholders in...

 PRESS RELEASE

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology ...

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting Presentation will address the Company’s clinical data in Parkinson’s disease CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: ), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease at the , taking place April 13-18, 2024 virtually and in Denver, Colorado. Presentation details are as follows:Oral PresentationSession: ES2 - Emerging ScienceTitle: Presen...

 PRESS RELEASE

Alliance Trust PLC - Net Asset Value

Alliance Trust PLC - Net Asset Value ALLIANCE TRUST PLC                 At the close of business Wednesday 27 March 2024: The Company’s NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 1285.2p                 -       including income, 1287.8p   The Company’s NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding income, 1288.4p -       including income, 1291.0p For further information, please contact: -  Juniper Partners LimitedTel. +44 (0)131 378 0500 Notes Net Asset Values are calculated ...

Amira Manai
  • Amira Manai

HighCo : Record 2023 results - Caution on 2024 due to risks associated...

>Adjusted earnings on ordinary activities of € 16.4m, i.e. an operating margin of 22.1% (+150bp) - Yesterday evening, HighCo reported record earnings for 2023. Despite a gross margin (already published) down 2.7% to € 74.4m, adjusted earnings on ordinary activities came in at € 16.4m, revealing a 150bp improvement to the operating margin to 22.1%, in line with the guidance announced in January and with our forecast (22.1%). This operational performance stems from eff...

NCL Corporation Ltd. - December 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Ithaca Energy plc: Potential transformational combination with Eni's U...

The transaction would enlarge Ithaca's scale and boost its cash-flow generation capacity.

 PRESS RELEASE

Form 8.3 - Mattioli Woods

Form 8.3 - Mattioli Woods 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION (a)   Full name of discloser:Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)   Name of offeror/offeree in relation to whose relevant securities this form relates: ...

 PRESS RELEASE

Cancellation of Listing of DSO D Shares and Cessation of Trading

Cancellation of Listing of DSO D Shares and Cessation of Trading THAMES VENTURES VCT 2 PLCDSO D SHARE CLASSLEI: 21380035MV1VRYEXPR95 Cancellation of listing of DSO D Shares and cessation of trading28 March 2024 Thames Ventures VCT 2 plc (the “Company”) announces that it has now completed a programme of returning funds to holders of the DSO D Shares, culminating with dividend payments of 2.7p per DSO D Share paid on 28 March 2024. Following the payment of this dividend, the Company has now returned all the capital associated with the DSO D Shares to shareholders and divested of all investm...

 PRESS RELEASE

Middlefield Canadian Income PCC: Net Asset Value(s)

Middlefield Canadian Income PCC: Net Asset Value(s) Middlefield Canadian Income PCC Net Asset Value Middlefield Canadian Income PCC Middlefield Canadian Income - GBP PC (a protected cell company incorporated in Jersey with registration number 93546)Legal Entity Identifier: 2138007ENW3JEJXC8658 Net Asset Value As at the close of business on 27 March 2024 the estimated unaudited Net Asset Value per share was 124.63 pence (including accrued income). Investments in the Company's portfolio have been valued on a bid price basis. Enquiries: JTC Fund Solutions (Jersey) Limited01534 700 000 ...

 PRESS RELEASE

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial...

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update Advanced OTX-2002 in MYCHELANGELO™ I trial; initial cohorts demonstrated encouraging disease control rate in late-stage HCC patientsEstablished a research collaboration with Novo Nordisk to develop an epigenomic controller for obesity, expanding the pipeline into the cardiometabolic space Announced strategic prioritization to focus resources on potential near-term value drivers, support long-term growth, and extend cash runway into Q1 2025 CAMBRIDGE, Mass., March 28, 2024 (GLOBE N...

Gerdau S.A. - December 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch